LY3177833
|
L648774-1mg
|
≥99% |
1627696-51-8 |
1mg
|
¥ 502.9
|
期货,请咨询 |
阿拉丁 |
LY3177833
|
L648774-10mg
|
≥99% |
1627696-51-8 |
10mg
|
¥ 1700.9
|
期货,请咨询 |
阿拉丁 |
LY3177833
|
L648774-100mg
|
≥99% |
1627696-51-8 |
100mg
|
¥ 9500.9
|
期货,请咨询 |
阿拉丁 |
(Rac)-LM11A-31 dihydrochloride
|
L648727-5mg
|
≥98% |
1214672-15-7 |
5mg
|
¥ 1100.9
|
期货,请咨询 |
阿拉丁 |
(Rac)-LM11A-31 dihydrochloride
|
L648727-10mg
|
≥98% |
1214672-15-7 |
10mg
|
¥ 1500.9
|
期货,请咨询 |
阿拉丁 |
Lumicitabine
|
L648719-5mg
|
≥99% |
1445385-02-3 |
5mg
|
¥ 3500.9
|
期货,请咨询 |
阿拉丁 |
Lumicitabine
|
L648719-50mg
|
≥99% |
1445385-02-3 |
50mg
|
¥ 15000.9
|
期货,请咨询 |
阿拉丁 |
Lumicitabine
|
L648719-1mg
|
≥99% |
1445385-02-3 |
1mg
|
¥ 1500.9
|
期货,请咨询 |
阿拉丁 |
Lumicitabine
|
L648719-10mg
|
≥99% |
1445385-02-3 |
10mg
|
¥ 5000.9
|
期货,请咨询 |
阿拉丁 |
Lumicitabine
|
L648719-100mg
|
≥99% |
1445385-02-3 |
100mg
|
¥ 21000.9
|
期货,请咨询 |
阿拉丁 |
Lucideric acid A
|
L648710-5mg
|
≥98% |
95311-94-7 |
5mg
|
¥ 5710.9
|
期货,请咨询 |
阿拉丁 |
Lucideric acid A
|
L648710-1mg
|
≥98% |
95311-94-7 |
1mg
|
¥ 1900.9
|
期货,请咨询 |
阿拉丁 |
Laprituximab
|
L648689-5mg
|
≥95% |
1622327-38-1 |
5mg
|
¥ 6800.9
|
期货,请咨询 |
阿拉丁 |
Laprituximab
|
L648689-1mg
|
≥95% |
1622327-38-1 |
1mg
|
¥ 2700.9
|
期货,请咨询 |
阿拉丁 |
Laprituximab
|
L648689-10mg
|
≥95% |
1622327-38-1 |
10mg
|
¥ 10800.9
|
期货,请咨询 |
阿拉丁 |
Lck inhibitor 2
|
L648683-5mg
|
≥99% |
944795-06-6 |
5mg
|
¥ 1500.9
|
期货,请咨询 |
阿拉丁 |
Lck inhibitor 2
|
L648683-50mg
|
≥99% |
944795-06-6 |
50mg
|
¥ 6800.9
|
期货,请咨询 |
阿拉丁 |
Lck inhibitor 2
|
L648683-10mg
|
≥99% |
944795-06-6 |
10mg
|
¥ 2400.9
|
期货,请咨询 |
阿拉丁 |
Lck inhibitor 2
|
L648683-100mg
|
≥99% |
944795-06-6 |
100mg
|
¥ 9500.9
|
期货,请咨询 |
阿拉丁 |
LY487379
|
L648652-5mg
|
≥98% |
353231-17-1 |
5mg
|
¥ 800.9
|
期货,请咨询 |
阿拉丁 |
LY487379
|
L648652-50mg
|
≥98% |
353231-17-1 |
50mg
|
¥ 4000.9
|
期货,请咨询 |
阿拉丁 |
LY487379
|
L648652-25mg
|
≥98% |
353231-17-1 |
25mg
|
¥ 2500.9
|
期货,请咨询 |
阿拉丁 |
LY487379
|
L648652-10mg
|
≥98% |
353231-17-1 |
10mg
|
¥ 1200.9
|
期货,请咨询 |
阿拉丁 |
LY487379
|
L648652-100mg
|
≥98% |
353231-17-1 |
100mg
|
¥ 6400.9
|
期货,请咨询 |
阿拉丁 |